Chemical Structure (Clopidogrel Tabs Aurobindo Walmart 1)
Clopidogrel Tablet, Film Coated
Product Images NDC 68645-590
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68645-590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Legacy Pharmaceutical Packaging, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Clopidogrel Tablets, Usp 75mg (Clopidogrel Tabs Aurobindo Walmart 10)
This is a description of a medication labeled as "Clopidogrel Tablets". These are film-coated tablets containing 97.875 mg of clopidogrel bisulfate USP, which is equivalent to 75 mg of clopidogrel base. The medication comes in a package with 90 tablets, and each tablet is required to be kept in a well-closed container that is protected from moisture. A warning is given to keep the medication away from children. The manufacturer is Aurobindo Pharma USA, Inc. and the medication is distributed by Wal-Mart. There are also details on storage conditions, dosage recommendations and instructions for pharmacists to dispense the medication guide separately. The text also includes a GTIN number and the date of revision.*
Figure 1 (Clopidogrel Tabs Aurobindo Walmart 2)
The text is describing a figure (Figure 1) that illustrates the exposure to Clopidogrel Active Metabolite after multiple doses of Clopidogrel Bisulfate 75mg alone or in combination with Proton Pump Inhibitors (PPIs). Each PPI (Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole) has an effect on the active metabolite's AUC (area under the curve). The figure includes the mean and 90% confidence interval of the effect of each PPI compared to when Clopidogrel Bisulfate is administered alone.*
Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Tabs Aurobindo Walmart 3)
This text represents a chart showing the Cumulative Event Rate for Cardiovascular Death, Myocardial Infarction, and Stroke over 12 months of follow-up for patients taking either Plagebo (+ aspirin) or Clopidogrel Bisulfate (+ aspirin) with other standard therapies used as appropriate. The chart shows that patients taking Clopidogrel Bisulfate (+ aspirin) had a significantly lower Cumulative Event Rate compared to those taking Plagebo (+ aspirin) with a P value of 0.00009.*
Figure-3 (Clopidogrel Tabs Aurobindo Walmart 4)
This appears to be a table with data related to patient demographics, medical conditions and medication usage, possibly as part of a clinical trial or research study. It includes information on subgroups by age and gender, as well as details on medical history (such as diabetes, previous MI, and stroke). The table also lists various medications used by the patients, including HeparinLMWH, Aspirin, GPIIbla Artag, Beta Blocker, Ace Inhbitor, and N Clopidogrel Bisulate. There is a section titled "Placebo n (%)" which may indicate a control group received a placebo instead of medication. The final row includes a "Hazard Ratio (85% CI)", but without context or further information it is unclear what this represents.*
Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Tabs Aurobindo Walmart 5)
This text appears to be a statistical analysis report for a clinical trial comparing placebo versus clopidogrel. The text shows the number of deaths before the first discharge in each group, with the placebo group having 1845 deaths (8.1%) and the clopidogrel group having 1726 deaths (7.5%). The report also highlights a 7% risk reduction in the clopidogrel group compared to placebo, with a p-value of 0.03. Finally, the graph shows the relationship between days since randomization (up to 28 days) and the number of deaths in each group.*
Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Tabs Aurobindo Walmart 6)
Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Tabs Aurobindo Walmart 7)
This text appears to be a table with a lot of numerical data. It seems to be related to a medical study evaluating the effects of a drug called Clopidogrel Bisultate. There are different subgroups based on age, gender, hours since onset, etc. The table includes percentages and odds ratios, possibly for comparing the effectiveness of the drug versus Placebo. However, as the text is hard to read in places due to errors, the interpretation of this information may not be accurate.*
Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Tabs Aurobindo Walmart 8)
The figure appears to be a graphical representation of the cumulative event rate of fatal or non-fatal vascular events for patients treated with aspirin and clopidogrel bisulfate over a period of 36 months of follow-up. There is no additional text to provide further context or details.*
Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Tabs Aurobindo Walmart 9)
This text appears to be a table showing the number of patients with stroke, MI, and PAD who qualified for a treatment condition, such as Clopidogrel or Aspirin, as well as the percentage of patients in each condition. The table also shows the number of patients overall, favors for each treatment, and a hazard ratio. It is unclear what the hazard ratio refers to without additional context.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
